An urgent issue in modern clinical medicine is the selection of a drug for the rational treatment of infections caused by resistant pathogens. Only a few modern antibiotics can combine activity against both resistant Gram(+) bacteria (MRSA, enterococci) and problematic Gram(-) pathogens—producers of extended-spectrum beta-lactamases [ESBLs] and strains that produce carbapenemases or metallo-beta-lactamases.

PJSC Kraspharma has launched Tigecycline-KF, a modern glycylcycline antibiotic, in the Russian Federation, designed to enhance the effectiveness of antimicrobial therapy in hospital settings.

Tigecycline-KF has a broad antimicrobial spectrum and is active against many resistant bacteria, including strains resistant to tetracyclines and carbapenems. An important feature of the drug is its activity against atypical respiratory infection pathogens (Chlamydia, Mycoplasma spp.), certain mycobacteria, and clinically significant anaerobes, including Bacteroides fragilis, Clostridium perfringens, and Clostridioides difficile. Its unique spectrum of activity, combined with favorable pharmacokinetics (tigecycline has a large volume of distribution and penetrates well into bones, lungs, liver, and other tissues and organs), makes it suitable for monotherapy of complicated skin and soft tissue infections, including infections in patients with diabetic foot, intra-abdominal infections, and respiratory tract infections. Importantly, no dose adjustment is required for patients with renal failure.